Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Bortezomib in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma

This study has been completed.
Information provided by (Responsible Party):
National Cancer Institute (NCI) Identifier:
First received: May 14, 2004
Last updated: December 3, 2015
Last verified: June 2013
Phase II trial to study the effectiveness of bortezomib in treating patients who have relapsed or refractory Hodgkin's lymphoma. Bortezomib may stop the growth of cancer cells by blocking the enzymes necessary for their growth.

Condition Intervention Phase
Adult Lymphocyte Depletion Hodgkin Lymphoma
Adult Mixed Cellularity Hodgkin Lymphoma
Adult Nodular Sclerosis Hodgkin Lymphoma
Recurrent Adult Hodgkin Lymphoma
Drug: 17-N-allylamino-17-demethoxygeldanamycin/bortezomib
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase II Study of PS-341 (Bortezomib) in Patients With Relapsed or Refractory Hodgkin's Lymphoma

Resource links provided by NLM:

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Overall response rate [ Time Frame: Up to 3 years ]
  • Time to progression [ Time Frame: Up to 5 years ]
  • Overall survival [ Time Frame: 2 years ]

Enrollment: 43
Study Start Date: March 2004
Primary Completion Date: March 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm I
Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Treatment repeats every 21 days for up to 8 courses in the absence of rapid disease progression or unacceptable toxicity.
Drug: 17-N-allylamino-17-demethoxygeldanamycin/bortezomib
Given IV

Detailed Description:


I. To evaluate the efficacy of bortezomib in patients with relapsed or refractory Hodgkin's lymphoma using overall response rate as the primary efficacy endpoint.

II. To assess time to progression and 2-year overall survival after bortezomib therapy.

III. To evaluate the safety and tolerability of bortezomib in patients with relapsed/refractory Hodgkin's lymphoma.

OUTLINE: This is a multicenter study.

Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Treatment repeats every 21 days for up to 8 courses in the absence of rapid disease progression or unacceptable toxicity.

Patients are followed every 3 months for 1 year and then every 6 months for 2 years.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically confirmed classical Hodgkin's lymphoma

    • No bone marrow biopsies or fine needle aspirates as the sole means of diagnosis
    • Core biopsies allowed if they contain adequate tissue for primary diagnosis
  • The following subtypes are allowed:

    • Nodular sclerosis
    • Lymphocyte rich
    • Mixed cellularity
    • Lymphocyte depletion
    • Classical Hodgkin's lymphoma, not otherwise specified
  • No nodular lymphocyte-predominant Hodgkin's lymphoma
  • Relapsed or refractory disease after at least 1 prior standard systemic cytotoxic chemotherapy regimen
  • Measurable disease by physical exam or imaging studies

    • Any tumor mass > 1 cm is allowed
    • No non-measurable disease only, including the following:

      • Bone lesions
      • Ascites
      • Pleural or pericardial effusion
      • Lymphangitis cutis/pulmonis
      • Bone marrow
  • No curative option available with high-dose therapy and stem cell transplantation
  • Performance status - 0-2
  • Absolute neutrophil count ≥ 750/mm^3
  • Platelet count ≥ 75,000/mm^3
  • Bilirubin ≤ 1.5 times upper limit of normal (ULN)
  • AST ≤ 2.5 times ULN
  • Creatinine ≤ 2.5 mg/dL
  • No sensory or motor peripheral neuropathy ≥ grade 2
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception during and for up to 3 months after study participation
  • See Disease Characteristics
  • Prior stem cell transplantation allowed
  • See Disease Characteristics
  • No concurrent chemotherapy
  • No concurrent dexamethasone or other steroidal antiemetics

    • Concurrent steroids for adrenal failure allowed
  • Concurrent hormonal therapy for non-disease related conditions (e.g., insulin for diabetes) allowed
  • Prior radiotherapy to a symptomatic lesion or one that may produce disability (e.g., unstable femur) is allowed provided other measurable disease is present
  • No concurrent palliative radiotherapy
  • Recovered from all prior treatment
  • No prior bortezomib or other proteosome inhibitors
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00082966

United States, Illinois
Cancer and Leukemia Group B
Chicago, Illinois, United States, 60606
Sponsors and Collaborators
National Cancer Institute (NCI)
Principal Investigator: Nancy Bartlett Cancer and Leukemia Group B
  More Information

Responsible Party: National Cancer Institute (NCI) Identifier: NCT00082966     History of Changes
Other Study ID Numbers: NCI-2012-01812
U10CA031946 ( US NIH Grant/Contract Award Number )
Study First Received: May 14, 2004
Last Updated: December 3, 2015

Additional relevant MeSH terms:
Hodgkin Disease
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Antineoplastic Agents processed this record on May 24, 2017